HTGCMEDIUM SIGNALFINANCIAL10-K

HTGC substantially expanded its debt investment portfolio with multiple new senior secured loans while meaningfully growing net income and total assets.

The addition of seven new senior secured debt investments in application software companies, combined with the exit from several equity positions, suggests HTGC is actively rotating toward higher-yielding debt instruments in the current interest rate environment. The company's focus on senior secured positions with floor rates ranging from 8.61% to 11.55% positions it well for income generation, though concentration in software sector lending introduces sector-specific risk.

Comparing 2026-02-12 vs 2025-02-13View on EDGAR →
FINANCIAL ANALYSIS

HTGC demonstrated solid financial expansion with net income growing meaningfully to $339.7M while total assets increased 19.6% to $4.6B, reflecting active portfolio deployment. The company increased its debt financing by 29.3% to $2.3B to fund growth, with correspondingly higher interest expenses of $77.5M, though the spread between portfolio yields and funding costs appears to be driving profitable expansion. Cash position strengthened to $56.9M and stockholders' equity grew 11.4%, indicating disciplined capital management alongside portfolio growth.

FINANCIAL STATEMENT CHANGES
Share Buybacks
Cash Flow
+89.2%
$3.4M$6.5M

Share repurchases increased 89.2% — management returning capital, signals confidence in intrinsic value.

Cash & Equivalents
Balance Sheet
+33.3%
$42.7M$56.9M

Cash position surged 33.3% — strong cash generation or capital raise providing significant financial cushion.

Total Debt
Balance Sheet
+29.3%
$1.8B$2.3B

Debt rose 29.3% — additional borrowing for investment or operations; monitor coverage ratios.

Net Income
P&L
+29.2%
$263.0M$339.7M

Net income grew 29.2% — bottom-line growth signals improving overall business health.

Total Liabilities
Balance Sheet
+28.6%
$1.8B$2.4B

Liabilities increased 28.6% — monitor debt-to-equity ratio and interest coverage.

Interest Expense
P&L
+24.2%
$62.3M$77.5M

Interest costs rose 24.2% — monitor debt levels and coverage ratio in rising rate environment.

Total Assets
Balance Sheet
+19.6%
$3.8B$4.6B

Asset base grew 19.6% — expansion through organic growth, acquisitions, or capital deployment.

Stockholders Equity
Balance Sheet
+11.4%
$2.0B$2.2B

Equity base grew 11.4% — retained earnings accumulation or equity issuance strengthening the balance sheet.

LANGUAGE CHANGES
NEW — 2026-02-12
PRIOR — 2025-02-13
ADDED
and Senior Secured and Maturity Date February 2029 and Prime + 3.50%, Floor rate 10.00%, 3.50% Exit Fee 2025-12-31 0001280784 Debt Investments Application Software and Ceros, Inc.
and Senior Secured and Maturity Date June 2027 and 3-month SOFR + 8.99%, Floor rate 9.89% 2025-12-31 0001280784 Debt Investments Application Software and Chainalysis, Inc.
and Senior Secured and Maturity Date June 2029 and Prime + 2.95%, Floor rate 10.45% 2025-12-31 0001280784 Debt Investments Application Software and Dashlane, Inc.
and Senior Secured and Maturity Date December 2027 and Prime + 3.05%, Floor rate 11.55%, PIK Interest 1.10%, 6.28% Exit Fee 2025-12-31 0001280784 Debt Investments Application Software and Dispatch Technologies, Inc.
and Senior Secured and Maturity Date April 2028 and 3-month SOFR + 7.86%, Floor rate 8.61% 2025-12-31 0001280784 Debt Investments Application Software and Distributed Creation Inc.
+7 more — sign up free →
REMOVED
2024-12-31 0001280784 Equity Investments Software and SirionLabs Pte.
Warrant, Acquisition Date 8/24/2023, Series Common Stock 2024-01-01 2024-12-31 0001280784 Warrant Investments and Software and Suzy, Inc.
Gibraltar Business Capital, LLC), Equity, Acquisition Date 3/1/2018, Series Member Units 2023-01-01 2023-12-31 0001280784 Equity Investments Diversified Financial Services and Gibraltar Acquisition, LLC (p.k.a.
AcelRx Pharmaceuticals, Inc.), Equity, Acquisition Date 12/10/2018, Series Common Stock 2023-01-01 2023-12-31 0001280784 Equity Investments Drug Delivery and Talphera, Inc.
Applied Molecular Transport)., Equity, Acquisition Date 4/06/2021, Series Common Stock 2023-01-01 2023-12-31 0001280784 Equity Investments Drug Discovery Development and Cyclo Therapeutics, Inc.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →